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ABSTRACT
A review is given of the background to and results of the succesful pharmacological testing of [AuX2(damp)]
(X CI, OAc; damp 2-Me,NCHzC6H4) against a range of microbes, fungi and turnouts, culminating in in
vivo xenografts of ZR-1-75. These are the first fully evaluated gold(III) complexes. The activity and reactions
of the diacetato-complex bear a resemblance to cisplatin, and some of the relevant chemistry is discussed.
Preliminary screening data for C,P-chelated tertiary phosphine derivatives of gold(III) are presented.
INTRODUCTION
Given that the anti-tumor activity of platinum(II) has been investigated for over 30 years, it is
surprising that gold(III) has received so little attention. The two are isoelectronic and isosteric: d’
configurations and square-planar complexes; they undergo similar types of subsitution reactions.
There are two obvious problems. (a) The additional positive charge on the gold atom means that
the ligand sets cannot be the same if the same overall charge is to be attained. Thus, for neutral complexes of
the cisplatin type gold(III) would have to have three negatively charged ligands. (b) Compounds of gold
show a distressing tendency to undergo reduction to the metal. Those who have attempted any synthetic
chemistry in the field know how readily deposits of elemental gold appear.
It might be desirable to mimic some other features of active platinum compounds, e.g. the cis-
disposition of two readily displaceable ligands and, perhaps, the presence of a primary or secondary amine
ligand.
PREVIOUS WORK
N,O-Systems
The above challenges are not difficult to overcome. We decided a few years ago to use chelating
mono-negative ligands to force the cis geometry and to neutralise the third positive charge, and chose to
begin with Schiff-bases and pyridine 2-carboxylates (l, 11). Complexes of the desired type can be obtained,
albeit not without some difficulty (it is much easier to obtain the bis-chelated complexes than the mono-
chelates, Equ 1). However, as soon as these materials encountered biological media, reduction to elemental
gold occurred, presumably with oxidation of the cell-material and, hence, disastrous toxicity.2
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It was necessary to stabilise the gold(Ill) centre against reduction, and we argued that this would
best be done by using a softer ligand system. This would reduce the positive charge on the gold atom and
make it less oxidising and less prone to reduction. Organometallics seemed to be the answer, since a _-
carbon ligand is certainly soft and would serve as the anionic group, and organic derivatives of gold are fairly
stable. There had been a brief report that Ph4As[AuCIzMe2] and [AuMez(_-SCN)] inhibited P388.3 We
preferred chelate complexes, in order to be sure of the configuration, and some relevant materials had already
been reported; these were derived from 2-phenylpyridine (Ill, Constable)4 or from diemthylbenzylamine or
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azobenzene (IV, V, Vicente); 5’6 we decided to look at these, and their ring-substituted analogues and to
prepare new complexes with related N,C ligands (VI-VIII).
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We used mainly the trans-metallation route via the mercury(II) derivative (Scheme 1). 7’8 This method works
far better than the direct auration route pioneered by Constable and used by others for some substituted
pyridine derivatives,9’ which give rather low yields.
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TABLE Minimum Inhibitory Concentrations (lag/mL) against Bacteria
111
IV
IX
Sytaphylococcu Enterococcus
aureus
1.0 2.5
1.0 2.5
faecalis
0.25- 1.0
2.5- 10
1.0 2.5
0.25- 1.0
> 100
25-100
1.0 2.5
Krebsiella
pneumoniae
25 200
10- 25
> 100
> 100
25 100
Escheria coli Pseudomonas
aeruginosa
25- 100
10- 25
2.5- l0
> 100
> 100
x (x cl) > 00
X (X Br) 10- 25
Ciprofloxacin < 0.25 < 0.25 0.25
10- 25
50- 100
> 100
> 100
0.25
a quinolone antibiotic, used as standard
We now have a large number of complexes of these types, and we have done much of the
conventional ligand-substitution chemistry. For instance, introduction of a tertiary phosphine may or may
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not lead to "unlatching" of the nitrogen donor atom (Equ. 2, 3). Adding another chelate gives more
straightforward products (Equ. 4-6), except when two dithiocarbamates are introduced, when fluxional
products are obtained containing one monedentate and one bidentate thiolate ligand (Equ 7).
However, the principal point of interest here is the possible biological activity of the complexes.
Fortunately, Johnson Matthey had a new screening facility and were anxious to try out precious-metal
complexes; we gave them complexes Ill and IV (X Cl), which were put through several screens involving
bacteria and fungi (Tables and II). 11
(2)...
(3)
(5)
"’v’\/o .o
Au / \s CO H
Me=Nc.
S /7)
S\A/S c / NR2
R2
TABLE II Minilnum Inhibitory Concentrations (g/mL) against fungi
III
IV
X (X c!)
Candida Candida
Albicans Albicans
25- 100 25- 100
10-25 25- 100
25 100
25- 100
Cryptococcus
neoformans
1.0 2.5
Aspergillus
niger
Aspergillus
fumigatus
25 100
X (X Br) 10-25 2.5 10
Amphotericin B < 0.25 < 0.25 < 0.25 0.25 1.0
a polyene antifungal, used as standard
2.5- I0 10- 25 2.5- 10
25- 100 25- 100 25- 100
10- 25
0.25- 1.0
TABLE 111 Comparative cytotoxicity against CHO cells (% survival)
_Conc. (pg/mL)
IV
10 1.0
2.2 69.6 84.3 91.3
IX 0.4 96.1 97.9 99.9
___c_isplatin 26.2 89.0 92.9 96.9
_Ciprofloxacin 90.0 101.2 99.9 96.9
72.7 Amphotericin B 88.2 2.4, 102.3
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TABLE IV ICso values (gg/mL) against human tumour lines in vitro
IV
SW620 SWll6
(colon) (colon.)
SW403
(colon)
56 5O 48
IX 281 238 45
ZR-75-1 HT29/219
(breast) (rectum)
11 22
67
cisplatin 120 135 200 15 30
HT1376
(bladder)
12
13
15
SK-OV-3
(ovary)
18
13
14
TABLE V ICso values (gg/mL) for ovarian carcinomas in vitro
HX63 A2780 A2780-R CH1 CHI’R
ll 12
0.12 0.56
iX 34 3.5 35
cisplatin 18 1.2 10
platinum-resistant
One is looking here for activity at reasonably low concentrations and, more particularly, for discrimination
between different organisms; simple biocidal activity is not enough. At this stage, complex |II was dropped,
and the toxicity of the dimethylbenzylamine complex IV against Chinese Hamster Ovary cells (CHO) was
compared with that of cisplatin (Table Ill). The gold complex was more toxic than cisplatin but, against
various turnout lines in vitro, it showed interesting selectivity (Table IV). The highspot of the testing was
the xenograft (human turnout lines grafted on to living nude mice). The pofiles (Fig. a) were not dissimilar
to those of cisplatin, although the dose levels needed were rather higher. lz
There was a possibility that the effectiveness of IV was being limited by its poor aqueous
solubility, and it was suggested that the diacetato analogue, IX, might be better. The data here were very
promising indeed in anti-bacterial and CHO tests (Tables I, Ill) and even better against the tumour lines
(Tables I, V). Of particular interest was the toxicity ,against CH1, one form of which is resistant to
cisplatin.-
The xenograft tests were also superb (Fig b). 14
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Figure Growth of breast tumour ZR-75-1 xenograft treated (a) with IV [dose levels: open square, none
(control); *, 6.25 mg/kg; +, 12.5 mg/kg; I, 25 mg/kg], and (b) with IX [*, 6.25 mg/kg; +, 12.5 mg/kg;
I, 25.0 mg/kg; , cisplatin, 4.5 mg/kg].
Various biological mechanistic studies were carried out by Johnson Matthey
s’4 which suggested, as
might be expected, some differences from the mode of action of cisplatin. Meanwhile, we at UMIST were
characterising IX and exploring its chemistry. One oddity was that the 3C NMR spectra showed a strange
difference in intensity of the two sets of acetate peaks (Fig 2a), which we eventually attributed to a hydrolysis
reaction due to traces of water in the solvents; the pure D20 solution showed a very exaggerated intentsity
difference (Fig 2b). Confirmation was obtained by using bone-dry acetonitrile and deliberately adding water
to it (Fig 2c,d). It was then possible to see two stages of hydrolysis, one very fast, giving rapid exchange
between co-ordinated and free acetate, and one much slower. The rapid one presumably involves the acetate
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trans to the labilising carbon ligand (Equ. 8, 9).
’3 These results were of great interest, since the mechanism
of action of cisplatin is thought to depend on hydrolysis.
OAc f== OAc
=Joy,, OH2
coo
CH.
coo
180 20 pm
Figure 2. "C NMR spectra of IX. (a) in CDCI, (b) in D20, (c) in CDCN (dry), (d) in CDCN/H20
(Au:H20 1:20).
In aqueous or dmso solution, IX reacts readily with a range of biological ligands. Cysteine and
glutathione reacted in predictable ways, to give chelated complexes but purines and nucleosides gave various
degrees of co-ordination, ranging from zero to quantitative. Co-ordination was always monodentate, and the
NMR indicated various donor sites (the NIq group, or N or N7). While this is different from what is
normally thought to be the case for platinum a recent paper suggests that pH- and temperature-dependent
equilibria and rearrangements may occur.15
Recently, workers in New Zealand have performed antimicrobial and anti-tumor screening on
[Au(damp)Z] where Z is a chelating urylene or thiosalicylate ligand [(RN)2C=O or 2-SC6H4CO; (damp 2-
Me.NCHzCH4)]. The data show good toxicity and promising anti-turnout activity. 16 Clearl systems of
this type bear further investigation, and we are arranging further screening tests on our gold(III) C,N-chelates.
Modifications of the ligands are being made to attempt to obtain better initial solubilities.
P,C-Systems
It would clearly be prudent to examine other ligand systems, and we picked up an old but curious
report by Martin Bennett, who showed that oxidation of gold(I) complexes of diphenylstyrylphosphine gave
P,C chelate systems .(Scheme 2). 17 The chemistry of this system is very strange, invlvoing redistribution
and redox reactions. 18 However, Johnson Matthey have performed preliminary antimicrobial screening.
Activity was not very good (Tables 1,2), slightly better for the dibromo derivative, probably because it is
less insoluble. Both had to be dissolved in acetone before adding water; we are currently working on
synthesising more soluble derivatives, and shall try again.
CONCLUSION
Gold(Ill) complexes have interesting biochemical activity provided that the ligands are chosen to
stabilise the gold against reduction and to provide adequate solubility. It is certain that their mode of action
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will be different from that of platinum(II) systems, but this is probably an advantage in that it opens a
different spectrum of activity.
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